U.S. Stem Cell

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of s... car tissue within a patients heart with autologous muscle cells or cells from a patients body for improving cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, lower limb ischemia, and rheumatoid arthritis. The companys product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It also offers MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training services, cell collection, and cell storage services; and sells cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 1999. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise,...Read More